Bacterial Constipation: A New Understanding of Chronic Digestive Issues

For millions worldwide, chronic constipation is a debilitating condition often resistant to conventional treatments. Recent research from Nagoya University in Japan has pinpointed a surprising culprit: a partnership between two gut bacteria, Akkermansia muciniphila and Bacteroides thetaiotaomicron, leading to what scientists are calling “bacterial constipation.” This discovery offers a new perspective on the causes of chronic idiopathic constipation (CIC) and may pave the way for more effective therapies, particularly for those with Parkinson’s disease.

The Role of Gut Mucus in Healthy Digestion

Constipation is commonly attributed to slow gut movement, where food and waste don’t transit the digestive tract efficiently. However, this explanation doesn’t apply to all cases. Chronic idiopathic constipation (CIC) affects individuals with no identifiable cause and patients with Parkinson’s disease often experience severe, treatment-resistant constipation for decades before the onset of motor symptoms. Researchers are now focusing on the protective gel-like coating of the colon, known as colonic mucin.

Colonic mucin lines the intestinal walls and is present within stool, keeping it moist, facilitating easy passage, and shielding the intestinal lining from bacteria. A healthy mucus layer is crucial for regular bowel movements.

How Bacteria Disrupt the Mucus Barrier

The research reveals a two-step process by which Akkermansia muciniphila and Bacteroides thetaiotaomicron dismantle this protective barrier. First, B. Thetaiotaomicron produces enzymes that remove sulfate groups from mucin. These sulfate groups normally protect the mucin from bacterial degradation. Once these protective groups are removed, A. Muciniphila can effectively digest the exposed mucin. [1]

As mucin levels decline, stool loses moisture, becoming hard and dry, ultimately leading to constipation. This suggests that traditional laxatives, which focus on stimulating gut movement, may not address the root cause of the problem – the loss of the protective mucus layer.

Parkinson’s Disease and Gut Bacteria

Interestingly, the study found higher levels of these mucus-degrading bacteria in patients with Parkinson’s disease. [2] Constipation is a common early symptom of Parkinson’s, often appearing years before the characteristic tremors. While previously attributed to nerve damage, these findings suggest that bacterial activity may also play a significant role in the development of the disease’s early symptoms.

Targeting Bacterial Enzymes: A Potential Treatment Strategy

To investigate whether blocking this process could prevent constipation, researchers genetically modified B. Thetaiotaomicron to disable its sulfatase enzyme – the enzyme responsible for removing sulfate groups from mucin. [3] When these modified bacteria were introduced into germ-free mice alongside A. Muciniphila, the mice did not develop constipation; the mucin layer remained intact.

This experiment suggests that medications designed to block sulfatase activity could potentially treat “bacterial constipation” in humans. [4]

Looking Ahead

The discovery of this bacterial duo and their role in disrupting the colonic mucus barrier represents a significant step forward in understanding chronic constipation. For the millions who suffer from this condition, particularly those with Parkinson’s disease, this research offers hope for new, targeted therapies that address the underlying microbial cause rather than simply managing the symptoms. Future research will focus on developing strategies to protect the colon’s mucus barrier and restore a healthy gut environment.